Literature DB >> 14763132

CKD-602. Chong Kun Dang.

Mirjam Crul1.   

Abstract

Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14763132

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

1.  A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.

Authors:  Ning Wu; Xi-Wei Wu; Keli Agama; Yves Pommier; Jun Du; Ding Li; Lian-Quan Gu; Zhi-Shu Huang; Lin-Kun An
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

2.  Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.

Authors:  William C Zamboni; Suresh Ramalingam; David M Friedland; Robert P Edwards; Ronald G Stoller; Sandra Strychor; Lauren Maruca; Beth A Zamboni; Chandra P Belani; Ramesh K Ramanathan
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

Review 3.  Recent developments in topoisomerase-targeted cancer chemotherapy.

Authors:  KirkE Hevener; Tatsiana A Verstak; Katie E Lutat; Daniel L Riggsbee; Jeremiah W Mooney
Journal:  Acta Pharm Sin B       Date:  2018-07-25       Impact factor: 11.413

4.  Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.

Authors:  Huali Wu; Ramesh K Ramanathan; Beth A Zamboni; Sandra Strychor; Suresh Ramalingam; Robert P Edwards; David M Friedland; Ronald G Stoller; Chandra P Belani; Lauren J Maruca; Yung-Jue Bang; William C Zamboni
Journal:  Int J Nanomedicine       Date:  2012-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.